This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Lipid lowering

Conversations on cholesterol: evaluating the role of LDL-cholesterol reduction in ASCVD

September 2021 Br J Cardiol 2021;28(suppl 2):S7–S12 doi:10.5837/bjc.2021.s07

Conversations on cholesterol: evaluating the role of LDL-cholesterol reduction in ASCVD

Chris J Packard

Abstract

Introduction Cardiovascular disease remains a major cause of morbidity and mortality in the UK even though mortality rates have declined significantly over the last 50 years.1 Improvements in the detection and treatment of people at elevated risk for atherosclerotic cardiovascular disease (ASCVD) have contributed to the decline, but findings from surveys of current practice indicate that much more could be done in both primary and secondary prevention settings to alleviate the disease burden.2 The following ‘conversations’ focus on recent developments in our understanding of the role of lipoproteins in ASCVD, and the potential of lipid-lo

| Full text
Inclisiran: testing a population health management methodology to implement a novel lipid treatment

September 2021 Br J Cardiol 2021;28(suppl 2):S19–S22 doi:10.5837/bjc.2021.s09

Inclisiran: testing a population health management methodology to implement a novel lipid treatment

Samantha Dixon, Linda Rootkin, Tracey Vell

Abstract

Introduction Cardiovascular disease (CVD) affects around seven million people in the UK. It is a significant cause of disability and is responsible for one in four premature deaths – accounting for the largest gap in health life-expectancy. It is also an area where there are significant health inequalities, with those in the most deprived 10% of the population almost twice as likely to die as a result of CVD, than those in the least deprived 10% of the population.1 Box 1. Five major practical changes to the NHS service model2 We will boost ‘out-of-hospital’ care, and finally dissolve the historic divide between primary and commu

| Full text
News from ACC.17

April 2017 Br J Cardiol 2017;24:49-54 Online First

News from ACC.17

BJCardio Staff

Abstract

Tsimane people show healthiest arteries yet studied Indigenous South Americans from the Bolivian Amazon – the Tsimane people – have the lowest recorded levels of vascular ageing A South American Tsimane person of 80 years is estimated to have the same vascular age as an American person in their mid-50s, according to a study presented at the ACC. The Tsimane people – an indigenous forager-horticulturalist population of the Bolivian Amazon – have the lowest reported levels of vascular ageing for any population, with coronary atherosclerosis being five times less common than in the USA. This has led the researchers to propose that the lo

| Full text

August 2015 Br J Cardiol 2015;22:88

London welcomes the 2015 ESC Congress

Dr Sarah Clarke

Abstract

The Congress offers a unique opportunity to showcase therapeutic and diagnostic advances, alongside cutting edge, bench- to-bedside science. There are five days of scientific sessions covering 150 cardiovascular topics with over 500 expert sessions. This year over 11,000 abstracts were submitted, and the theme is ‘Environment and the heart’. We at the BCS are holding dedicated sessions at the Congress, and on Saturday 29th August we are hosting a General Cardiology Day for General Practitioners and Allied Professionals, so do encourage your colleagues and primary care colleagues to join us. Extracurricular activities include a series of e

| Full text

May 2008 Br J Cardiol 2008;15:158–60

Managing patients with ‘statin intolerance’: a retrospective study

Rajesh K Nair, Rangaprasad L Karadi, Eric S Kilpatrick

Abstract

Introduction It is estimated that 2.5 million patients in the UK currently take statin drugs for both primary and secondary prevention of vascular disease, and this number is likely to rise substantially with the lowering of treatment thresholds.1 As an increasing number of patients become eligible for lipid-lowering treatment, there is an increasing number who appear to be intolerant to individual statins. Indeed, though statins are known to be well tolerated and safe as elucidated in clinical trials, in the real world the incidence of statin intolerance due to non-severe side effects may well be underestimated.2,3 Since differences in the k

| Full text

January 2008 Br J Cardiol 2008;15:16-8

PCCS celebrates 10 years

BJCardio editorial team

Abstract

Momentous achievements The changes made in the diagnosis and management of cardiovascular disease over the past 10 years, led by primary care, were described as “momentous” by Primary Care Cardiovascular Society (PCCS) past chairman and board member Professor Richard Hobbs (Department of General Practice and Primary Care, University of Birmingham). Presenting the opening address ‘A decade of advances in cardiovascular disease’ at the two-day annual scientific meeting, he said: “Primary care teams have led advances in the treatment of cardiovascular disease and cardiovascular risk factors. They should feel very proud of the contribut

| Full text

April 2002 Br J Cardiol 2002;9:241-4

Can we do more to get patients to cholesterol targets?

Richard Hobbs

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now